Table 1.

Information on 3 antibody drugs in clinical trials and their targets and TAPINTO parameters

Gene	Freq (%)		ORR (%)	AvExp (FPKM)		PFS	FC		SAEs	Score
	Scale	Value		Top %	Value		Top %	Value
ERBB2	H. freq.	13.87	81.30	0–25%	412.00	9.90	0–25%	16.51	15.63%	6
VEGFA	I. freq.	4.33	32.20	25–50%	39.38	9.20	25–50%	7.41	37.57%	3
CD274	L. freq.	0.54	9.60	50–100%	14.37	2.10	0–25%	12.01	20.00%	2

ORR, objective response rate; PFS, progression-free survival; SAEs, serious adverse effects; Freq, frequency; AvExp, average expression; FC, fold change